Don't Assume Your ANDA Will Be Designated, US FDA Tells Aspiring Competitive Generic Therapy Sponsors
Executive Summary
Final guidance clarifies that all sponsors who want CGT designation, which can bring exclusivity upon approval, should request it.
You may also be interested in...
Competitive Generic Therapies Get Help With Development, But Not Goal Date
Draft guidance says US FDA will try to expedite assessment of competitive generic therapy designees, but will not give shorter review goals.
ANDA Sponsors In Drivers Seat For Competitive Generic Therapy Exclusivity
Draft guidance says US FDA will not assume a product has launched, the final requirement to receive the promised 180-day exclusivity, unless notified by the sponsor.
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.